- Home
- NMRA
as 05-16-2024 4:00pm EST
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.5B | IPO Year: | 2023 |
| Target Price: | $23.80 | AVG Volume (30 days): | 632.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.82 - $21.00 | Next Earning Date: | 05-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Neumora Therapeutics Inc. (NMRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burow Kristina | NMRA | Director10% Owner | Nov 13 '23 | Buy | $11.75 | 31,653 | $371,922.75 | 4,127,850 | SEC Form 4 |
| Burow Kristina | NMRA | Director10% Owner | Nov 13 '23 | Buy | $11.98 | 3,357 | $40,216.86 | 4,131,207 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 13 '23 | Buy | $11.75 | 31,653 | $371,922.75 | 4,127,850 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 13 '23 | Buy | $11.98 | 3,357 | $40,216.86 | 4,131,207 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 8 '23 | Buy | $11.75 | 5,431 | $63,814.25 | 4,096,197 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 8 '23 | Buy | $11.37 | 11,844 | $134,666.28 | 4,090,766 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 8 '23 | Buy | $10.53 | 31,079 | $327,261.87 | 4,078,922 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 8 '23 | Buy | $11.79 | 23,124 | $272,631.96 | 4,047,843 | SEC Form 4 |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Nov 8 '23 | Buy | $10.78 | 69,127 | $745,189.06 | 4,024,719 | SEC Form 4 |
Latest Neumora Therapeutics Inc. News
NMRA Breaking Stock News: Dive into NMRA Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression
GlobeNewswire
3 days ago
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
MT Newswires
10 days ago
Neumora Therapeutics Shares Fall as Q1 Loss Narrows
GlobeNewswire
10 days ago
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
11 days ago
Neumora Therapeutics to Participate in Upcoming Conferences in May
Simply Wall St.
23 days ago
We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Zacks
a month ago
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Zacks
a month ago